Alterity Therapeutics (NASDAQ:ATHE) Stock Rating Lowered by Benchmark

Alterity Therapeutics (NASDAQ:ATHE) was downgraded by Benchmark from a “speculative buy” rating to a “hold” rating in a research note issued on Monday, MarketBeat Ratings reports.

Separately, Maxim Group boosted their price objective on shares of Alterity Therapeutics from $8.00 to $12.00 and gave the company a “buy” rating in a research report on Thursday.

Alterity Therapeutics Stock Up 5.0 %

Shares of NASDAQ:ATHE opened at $4.80 on Monday. Alterity Therapeutics has a fifty-two week low of $1.00 and a fifty-two week high of $5.87. The firm has a 50-day simple moving average of $2.78 and a 200 day simple moving average of $1.83.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Alterity Therapeutics stock. HB Wealth Management LLC grew its position in Alterity Therapeutics Limited (NASDAQ:ATHE) by 34.1% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 31,883 shares of the company’s stock after purchasing an additional 8,100 shares during the period. HB Wealth Management LLC owned approximately 0.44% of Alterity Therapeutics worth $110,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 2.14% of the company’s stock.

Alterity Therapeutics Company Profile

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer’s disease, Huntington disease, Parkinson’s disease, and other neurological disorders in Australia. The company’s lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson’s disease.